BMS' Breyanzi meets primary endpoint in Phase III lymphoma trial
BMS has reported positive data from the Phase III trial where Breyanzi met the primary endpoint in relapsed or refractory LBCL patients.
Stay updated with breaking news from Noah Berkowitz. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BMS has reported positive data from the Phase III trial where Breyanzi met the primary endpoint in relapsed or refractory LBCL patients.
Study met primary and key secondary endpoints, demonstrating a highly statistically significant improvement in event-free survival, complete response rate and progression-free survival compared to standard of care Breyanzi safety results consistent with data from pivotal TRANSCEND NHL 001 trial Results represent the first time a therapy has demonstrated benefit compared to high-dose chemotherapy and stem cell ...
BMY Reports Positive Results From Phase 3 Breyanzi Trial In Second-line Relapsed Or Refractory LBCL NEW YORK CITY (dpa-AFX) - Bristol Myers Squibb (BMY) announced Thursday positive topline results from Phase 3 TRANSFORM trial evaluating Breyanzi (lisocabtagene maraleucel) versus chemotherapy followed by stem cell transplant in second-line relapsed or refractory large B-cell lymphoma or LBCL. The trial met primary and key secondary endpoints, demonstrating a highly statistically significant improvement in event-free survival, complete response rate and progression-free survival compared to sta...
If approved, Onureg will become the first and only once daily oral frontline maintenance therapy in Europe for patients with a broad range of acute myeloid leukemia subtypes In the pivotal QUAZAR ® AML-001 study, Onureg demonstrated significant overall survival and showed a relapse-free survival benefit in patients with AML in first remission Bristol Myers Squibb today announced the Committee for Medicinal Products … If approved, Onureg will become the first and only once daily oral frontline maintenance therapy in Europe for patients with a broad range of acute myeloid leukemia (AML) sub...